R. Valdez

XBB.1.5 monovalent mRNA vaccine booster significantly increases neutralizing antibodies against multiple SARS-CoV-2 variants in both uninfected and previously infected individuals.

This paper evaluates the antigenicity and receptor affinity of the SARS-CoV-2 BA.2.86 subvariant, finding it not more resistant to human sera than other variants but with specific mAb resistance and high receptor affinity.

This study evaluates antibody neutralization resistance of SARS-CoV-2 variants EG.5.1 and XBC.1.6 using pseudovirus assays and sera/mAbs, finding distinct evasion profiles and suggesting immunological imprinting and non-evasion-driven prevalence.

This study evaluates the effect of a second BA.5 bivalent booster on SARS-CoV-2 neutralizing antibodies in elderly individuals, finding no significant increase in Omicron-specific titers after the second dose.

This study shows that the ancestral spike in bivalent COVID-19 vaccines causes deep immunological imprinting, limiting antibody breadth against Omicron subvariants.

The paper analyzes the receptor affinity and antibody evasion properties of SARS-CoV-2 BA.2.75 subvariants, identifying two evolutionary pathways and three mutations that influence their virological features.

This study compares neutralizing antibody titers after bivalent and monovalent mRNA boosters and BA.5 breakthrough infection, finding no significant difference at one month but higher titers in breakthrough patients at three months.

This study shows that new SARS-CoV-2 BQ and XBB subvariants have significantly reduced neutralization by vaccines and monoclonal antibodies, suggesting a threat to current immunity.

This study compares neutralizing antibody responses to bivalent and monovalent mRNA vaccines against SARS-CoV-2 variants, finding similar titers for bivalent vaccines against Omicron BA.4/BA.5 and ancestral strains.